Organogenesis Inc.

Organogenesis Inc. is a regenerative medicine company headquartered in Canton, Massachusetts, specializing in advanced wound care, surgical solutions, and sports medicine products. The company develops and manufactures innovative tissue-based regenerative therapies and biologics designed to support clinical healing across multiple therapeutic areas. Their primary focus areas include advanced wound care products for burn and chronic wounds, and surgical/sports medicine applications. Organogenesis operates under FDA oversight and maintains regulatory compliance for their regenerative tissue products. The company supports healthcare providers through a "Circle of Care" program that includes patient and provider resources, reimbursement expertise, and regulatory guidance. In 2025, Organogenesis announced expansion of manufacturing and R&D capabilities with a new state-of-the-art biomanufacturing facility in Smithfield, Rhode Island, designed to support both existing and planned regenerative medicine products. The company employs reimbursement and regulatory specialists to manage compliance and market access for their product portfolio. Organogenesis serves U.S. healthcare providers and institutions, with a commitment to delivering science-based regenerative solutions that empower clinical healing.